Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome

Vincent C. Lombardi,1*, Francis W. Ruscetti,2* Jaydip Das Gupta,3 Max A. Pfost,1 Kathryn S. Hagen,1 Daniel L. Peterson,1 Sandra K. Ruscetti,1 Rachel K. Bagni,5 Cari Petrow-Sadowski,6 Bert Gold,2 Michael Dean,2 Robert H. Silverman,3 Judy A. Mikovits3†

Chronic fatigue syndrome (CFS) is a debilitating disease of unknown etiology that is estimated to affect 17 million people worldwide. Studying peripheral blood mononuclear cells (PBMCs) from CFS patients, we identified DNA from a human gammaretrovirus, xenotropic murine leukemia virus–related virus (XMRV), in 68 of 101 patients (67%) as compared to 8 of 218 (3.7%) healthy controls. Cell culture experiments revealed that patient-derived XMRV is infectious and that both cell-associated and cell-free transmission of the virus are possible. Secondary viral infections were established in uninfected primary lymphocytes and indicator cell lines after their exposure to activated PBMCs, B cells, T cells, or plasma derived from CFS patients. These findings raise the possibility that XMRV may be a contributing factor in the pathogenesis of CFS.

References and Notes

26. See supporting material on Science Online.
29. We thank A. Hyatt and V. Olsen for assistance with PCR and S. Bell, J. Browne, S. Cashins, S. Garland, M. Holdworth, C. Manicom, L. Owens, R. Puschendorf, K. Rose, E. Rosenblum, D. Rudd, A. Storfer, J. Van Derwaal, B. Voyles, and J. Warner for project assistance and editing. Supported by Australian Research Council Discovery Project grant DP0502826, Australian Government Department of Environment and Heritage grant RFT 43/2004, and the Wildlife Preservation Society of Australia. Animals were collected with permission from Queensland Parks and Wildlife Service (scientific permits WISP03686106 and WISP04143907; movement permit WIWM04381507) and New South Wales Parks and Wildlife Service (import license IED0705693).

Supporting Online Material

www.sciencemag.org/cgi/content/full/326/5952/582/DC1
Materials and Methods
SOM Text
Figs. S1 and S2
Tables S1 and S2
References
26 May 2009; accepted 26 August 2009
10.1126/science.1176765

585

www.sciencemag.org SCIENCE VOL 326 23 OCTOBER 2009

REPORTS

Downloaded from www.sciencemag.org on May 20, 2010
tissue repository, which contains samples from well-characterized cohorts of CFS patients, we isolated nucleic acids from PBMCs and assayed the samples for XMRV gag sequences by nested polymerase chain reaction (PCR) (5, 6). Of the 101 CFS samples analyzed, 68 (67%) contained XMRV gag sequence. Detection of XMRV was confirmed in 7 of 11 WPI CFS samples at the Cleveland Clinic by PCR-amplifying and sequencing segments of XMRV env [352 nucleotides (nt)] and gag (736 nt) in CFS PBMC DNA (Fig. 1A) (6). In contrast, XMRV gag sequences were detected in 8 of 218 (3.7%) PBMC DNA specimens from healthy individuals. Of the 11 healthy control DNA samples analyzed by PCR for both env and gag, only one sample was positive for gag and none for env (Fig. 1B). In all positive cases, the XMRV gag and env sequences were more than 99% similar to those previously reported for prostate tumor–associated strains of XMRV (VP62, VP35, and VP42) (fig. S1) (5).

Fig. 1. XMRV sequences in PBMC DNA from CFS patients. Single-round PCR results for gag, env, and gapdh sequences in PBMCs of (A) CFS patients and (B) healthy controls are shown. The positions of the amplicons are indicated and DNA markers (ladder) are shown. These are representative results from one group of 20 patients.

Fig. 2. Expression of XMRV proteins in PBMCs from CFS patients. (A) PBMCs were activated with phytohemagglutinin and interleukin-2, reacted with a mAb to MLV p30 Gag, and analyzed by IFC. (B) Lysates of activated PBMCs from CFS patients (lanes 1 to 5) were analyzed by Western blots with rat mAb to SFFV Env (top panel), goat antiserum to xenotropic MLV (middle panel), or goat antiserum to MLV p30 Gag (bottom panel). Lane 7, lysate from SFFV-infected HCD-57 cells. Molecular weight markers in kilodaltons are at left. (C) Lysates of activated PBMCs from healthy donors (lanes 1, 2, 4, 5, and 7) or from CFS patients (lanes 3 and 6) were analyzed by Western blots using rat mAb to SFFV Env (top panel) or goat antiserum to MLV p30 Gag (bottom panel). Lane 8, SFFV-infected HCD-57 cells. Molecular weight (MW) markers in kilodaltons are at left. (D) CD4+ T cells (left) or CD19+ B cells (right) were purified, activated, and examined by flow cytometry for XMRV Gag with a mAb to MLV p30 Gag.
Sequences of full-length XMRV genomes from two CFS patients and a partial genome from a third patient were generated (table S1). CFS XMRV strains 1106 and 1178 each differed by 6 nt from the reference prostate cancer strain XMRV VP62 (EF185282), and with the exception of 1 nt, the variant nucleotides mapped to different locations within the XMRV genome, suggesting independent infections. In comparison, prostate cancer-derived XMRV strains VP35 and VP42 differed from VP62 by 13 and 10 nt, respectively. Thus, the complete XMRV genomes in these CFS patients

**Fig. 3.** Infectious XMRV in PBMCs from CFS patients. (A) Lysates of LNCaP cells cocultured with PBMCs from CFS patients (lanes 1, 3, and 5) or healthy donors (lanes 2 and 4) were analyzed by Western blots with rat mAb to SFFV Env (top panel) or goat antiserum to xenotropic MLV (bottom panel). Lane 6, uninfected LNCaP; lane 7, SFFV-infected HCD-57 cells. MW markers in kilodaltons are at left. (B) Transmission electron micrograph of a budding viral particle from LNCaP cells infected by incubation with an activated T cell culture from a CFS patient. (C) Transmission electron micrograph of virus particles released by infected LNCaP cells.

**Fig. 4.** Infectious XMRV and antibodies to XMRV in CFS patient plasma. (A) Plasma from CFS patients (lanes 1 to 6) were incubated with LNCaP cells and lysates were prepared after six passages. Viral protein expression was detected by Western blots with rat mAb to SFFV Env (top panel) or goat antiserum to MLV p30 Gag (bottom panel). Lane 7, uninfected LNCaP; lane 8, SFFV-infected HCD-57 cells. MW markers in kilodaltons are at left. (B) Cell-free transmission of XMRV to the SupT1 cell line was demonstrated using transwell coculture with patient PBMCs, followed by nested gag PCR. Lane 1, MW marker. Lane 2, SupT1 cocultured with Raji. Lanes 3 to 7, SupT1 cocultured with CFS patient PBMCs. Lane 8, no template control (NTC). (C) Normal T cells were exposed to cell-free supernatants obtained from T cells (lanes 1, 5, and 6) or B cells (lane 4) from CFS patients. Lanes 7 and 8 are secondary infections of normal activated T cells. Initially, uninfected primary T cells were exposed to supernatants from PBMCs of patients WPI-1220 (lane 7) and WPI-1221 (lane 8). Lanes 2 and 3, uninfected T cells; lane 9, SFFV-infected HCD-57 cells. Viral protein expression was detected by Western blot with a rat mAb to SFFV Env. MW markers in kilodaltons are at left. (D) Plasma samples from a CFS patient or from a healthy control as well as SFFV Env mAb or control were reacted with BaF3ER cells (top) or BaF3ER cells expressing recombinant SFFV Env (bottom) and analyzed by flow cytometry. IgG, immunoglobulin G.
were >99% identical in sequence to those detected in patients with prostate cancer. To exclude the possibility that we were detecting a murine leukemia virus (MLV) laboratory contaminant, we determined the phylogenetic relationship among endogenous (non-ecotropic) MLV sequences, XMRV sequences, and sequences from CFS patients 1104, 1106, and 1178 (fig. S2). XMRV sequences from the CFS patients clustered with the XMRV sequences from prostate cancer cases and formed a branch distinct from non-ecotropic MLVs common in inbred mouse strains. Thus, the virus detected in the CFS patients’ blood samples is unlikely to be a contaminant.

To determine whether XMRV proteins were expressed in PBMCs from CFS patients, we developed intracellular flow cytometry (IFC) and Western blot assays, using antibodies (Abs) against viral proteins. These antibodies included, among others, (i) rat monoclonal antibody (mAb) to the spleen-focus-forming virus (SFFV) envelope (Env), which reacts with all polytropic and xenotropic MLVs (7); (ii) goat antisera to whole mouse NZB xenotropic MLV; and (iii) a rat mAb to MLV p30 Gag (8). All of these Abs detected the human VP62 XMRV strain grown in human Raji, LNCaP, and Sup-T1 cells (fig. S3) (5). IFC of activated lymphocytes (6, 9) showed that 19 of 30 PBMC samples from CFS patients reacted with the mAb to MLV p30 Gag (fig. 2A). The majority of the 19 positive samples also reacted with antisera to other purified MLV proteins (fig. S4A). In contrast, 16 healthy control PBMC cultures tested negative (fig. 2A and fig. S4A). These results were confirmed by Western blots (fig. 2B and C) (6) using Abs to SFFV Env, mouse xenotropic MLV, and MLV p30 Gag. Samples from five healthy donors exhibited no expression of XMRV proteins (fig. 2C). The frequencies of CFS cases versus healthy controls that were positive and negative for XMRV sequences were used to calculate a Pearson χ^2 value of 154 (two-tailed P value of 8.1 × 10^-35). These data yield an odds ratio of 54.1 (95% confidence interval of 23.8 to 122), suggesting a nonrandom association with XMRV and CFS patients.

To determine which types of lymphocytes in blood express XMRV, we isolated B and T cells from one patient’s PBMCs (6). Using mAb to MLV p30 Gag and IFC, we found that both activated T and B cells were infected with XMRV (fig. 2D and fig. S4A). Furthermore, using mAb to SFFV Env, we found that >95% of the cells in a B cell line developed from another patient were positive for XMRV Env (fig. S4B). XMRV protein expression in CFS patient–derived activated T and B cells grown for 42 days in culture was confirmed by Western blots (fig. S4C) using Abs to SFFV Env and xenotropic MLV.

We next investigated whether the viral proteins detected in PBMCs from CFS patients represent infectious XMRV. Activated lymphocytes (6) were cocultured with LNCaP, a prostate cancer cell line with defects in both the JAK-STAT and RNase L pathways (10, 11) that were previously shown to be permissive for XMRV infection (12). After coculture with activated PBMCs from CFS patients, LNCaP cells expressed XMRV Env and multiple XMRV Gag proteins when analyzed by Western blot (fig. 3A) and IFC (fig. S5A). Transmission electron microscopy (EM) of the infected LNCaP cells (fig. 3B), as well as virus preparations from these cells (fig. 3C), revealed 90- to 100-nm-diameter budding particles consistent with a gamma (type C) retrovirus (13).

We also found that XMRV could be transmitted from CFS patient plasma to LNCaP cells when we applied a virus centrifugation protocol to enhance infectivity (6, 14, 15). Both XMRV gp70 Env and p30 Gag were abundantly expressed in LNCaP cells incubated with plasma samples from 10 of 12 CFS patients, whereas no viral protein expression was detected in LNCaP cells incubated with plasma samples from 12 healthy donors (fig. 4A). Likewise, LNCaP cells incubated with patient plasma tested positive for XMRV p30 Gag in IFC assays (fig. S5B). We also observed cell-free transmission of XMRV from the PBMCs of CFS patients to the T cell line SupT1 (fig. 4B) and both primary and secondary transmission of cell-free virus from the activated T cells of CFS patients to normal T cell cultures (fig. 4C). Together, these results suggest that both cell-associated and cell-free transmission of XMRV are possible.

We next investigated whether XMRV stimulates an immune response in CFS patients. For this purpose, we developed a flow cytometry assay that allowed us to detect Abs to XMRV Env by exploiting its close homology to SFFV Env (16). Plasma from 9 out of 18 CFS patients infected with XMRV reacted with a mouse B cell line expressing recombinant SFFV Env (BaF3/ER-SFFV-Env) but not to SFFV Env negative control cells (BaF3/ER), analogous to the binding of the SFFV Env mAb to these cells (fig. 4D and fig. S6A). In contrast, plasma from seven healthy donors did not react (fig. 4D and fig. S6A). Furthermore, all nine positive plasma samples from CFS patients but none of the plasma samples from healthy donors blocked the binding of the SFFV Env mAb to SFFV Env on the cell surface (fig. S6B). These results are consistent with the hypothesis that CFS patients mount a specific immune response to XMRV.

Neurological maladies and immune dysfunction with inflammatory cytokine and chemokine up-regulation are some of the most commonly reported features associated with CFS. Several retroviruses, including the MLVs and the primate retroviruses HIV and HTLV-I, are associated with neurological diseases as well as cancer (17). Studies of retrovirus-induced neurodegeneration in rodent models have indicated that vascular and inflammatory changes mediated by cytokines and chemokines precede the neurological pathology (18, 19). The presence of infectious XMRV in lymphocytes may account for some of these observations of altered immune responsiveness and neurological function in CFS patients.

We have discovered a highly significant association between the XMRV retrovirus and CFS. This observation raises several important questions. Is XMRV infection a causal factor in the pathogenesis of CFS or a passenger virus in the immunosuppressed CFS patient population? What is the relationship between XMRV infection status and the presence or absence of other viruses that are often associated with CFS (e.g., herpesviruses)? Conceivably these viruses could be cofactors in pathogenesis, as is the case for HIV-mediated disease, in which co-infecting pathogens play an important role (20). Patients with CFS have an elevated incidence of cancer (21). Does XMRV infection alter the risk of cancer development in CFS? As noted above, XMRV has been detected in prostate tumors from patients expressing a specific genetic variant of the RNAase L gene (5). In contrast, in our study of this CFS cohort, we found that XMRV infection status does not correlate with the RNAase L genotype (6) (table S2).

Finally, it is worth noting that 3.7% of the healthy donors in our study tested positive for XMRV sequences. This suggests that several million Americans may be infected with a retrovirus of as yet unknown pathogenic potential.

References and Notes
6. Materials and methods are available as supporting material on Science Online.
22. We thank D. Bartolotta, Y. Huang, C. Hanson, and J. Trauler for technical assistance; K. Nagashima for EM; and C. Ware and K. Hunter for discussions. Funded by the Whittemore Peterson Institute and the Whittemore Family Foundation; the National Cancer Institute (NCI); NIH (funder contract 1HHSN261200800001D); and grants to R.H.S. from NC/NIMH (G10034931), the U.S. DoD Prostate Cancer Research Program (W81XWH-07-1138); the V Foundation for Cancer Research, the Clayton Foundation, and Mal and Lea Bank. The content of this publication does not reflect the views or policies of the U.S. DHHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.
Complete Reconstitution of a Highly Reducing Iterative Polyketide Synthase


Highly reducing iterative polyketide synthases are large, multifunctional enzymes that make important metabolites in fungi, such as lovastatin, a cholesterol-lowering drug from *Aspergillus terreus*. We report efficient expression of the lovastatin nonaketide synthase (LovB) from an engineered strain of *Saccharomyces cerevisiae*, as well as complete reconstitution of its catalytic function in the presence and absence of cofactors (the reduced form of nicotinamide adenine dinucleotide phosphate and S-adenosylmethionine) and its partner enzyme, the enoyl reductase LovC. Our results demonstrate that LovB retains correct intermediates until completion of synthesis of dihydromonacolin L, but off-loads incorrectly processed compounds as pyrones or hydrolytic products. Experiments replacing LovC with analogous MlcG from compact biosynthesis demonstrate a gate-keeping function for this partner enzyme. This study represents a key step in the understanding of the functions and structures of this family of enzymes.

Nature uses an amazing array of enzymes to make natural products (1). Among these metabolites, polyketides represent a class of over 7000 known structures of which more than 20 are commercial drugs (2). Among the most interesting but least understood enzymes making these compounds are the highly reducing iterative polyketide synthases (HR-IPKSs) found in filamentous fungi (3). In contrast to the well-studied bacterial type I PKSs that operate in an assembly line fashion (4), HR-IPKSs are megasynthases that function iteratively by using a set of catalytic domains repeatedly in different combinations to produce structurally diverse fungal metabolites (5). One such metabolite is lovastatin, a cholesterol-lowering drug from *Aspergillus terreus* (6). This compound is a precursor to simvastatin (Zocor, Merck, Whitehouse Station, NJ), a semi-synthetic drug that had annual sales of more than $4 billion before loss of patent protection in 2006 (7).

Biosynthesis of lovastatin proceeds via dihydromonacolin L (acid form 1, lactone form 2), a product made by the HR-IPKS lovastatin nonaketide synthase (LovB), with the assistance of a separate enoyl reductase, LovC (8) (Fig. 1). LovB is a 335-kD protein that contains single copies of ketosynthase (KS), malonyl–coenzyme A (CoA) acyltransferase (MAT), dehydratase (DH), methyltransferase (MT), ketoreductase (KR), and acyl-carrier protein (ACP) domains, as well as a section of the domain found in nonribosomal peptide synthetases (NRPSs) (9). It also contains a domain that resembles an enoyl reductase (ER) but lacks that activity. LovB must catalyze —35 reactions and use different permutations of tailoring domains after each of the eight chain-extension steps to yield the nonaketide, dihydromonacolin L (2). This enzyme also catalyzes a biological Diels–Alder reaction during the assembly process to form the decalin ring system (10). In vitro studies of LovB (11) have been hampered by an inability to obtain sufficient amounts of the functional purified megasynthase from either *A. terreus* or heterologous *Aspergillus* hosts. As a result, the programming that governs metabolism by LovB or other HR-IPKSs is not understood. Key aspects that remain to be elucidated include (i) the catalytic and structural roles of each domain in the megasynthesis, (ii) substrate specificities of the catalytic domains and their tolerance to perturbation in megasynthesis functions, and (iii) factors governing the choice of different combinations of domains during each iteration of catalysis. To initiate such studies, we engineered an expression system in yeast to produce large amounts of LovB and examined the influence of cofactors and the ER partner (e.g., LovC) on product formation.

The engineered *Saccharomyces cerevisiae* strain BJ5464-NpgA, which contains a chromosomally tagged LovB was placed under the control of the S. cerevisiae ADH2 promoter (13, 14) on an episomal plasmid (YPELoGb-6His). Abundant amounts of the intact LovB could be purified from the soluble fraction to near homogeneity with a final yield of ~4.5 mg/L (fig. S1). We used mass analysis of tryptic digest fragments to verify the identity of the recombinant LovB. The ACP domain of LovB was determined to be nearly completely phosphopantetheinyalted by using a ppp-ejection assay with high-resolution quadrupole orthogonal acceleration–time-of-flight mass spectrometry (fig. S2). To ascertain activity of the resulting LovB and to examine the necessity for cofactors, malonyl-CoA alone was first added to the purified enzyme in buffer. Whole-cell feeding studies of doubly [13C, 2H]-labeled acetate to cultures of *A. terreus* showed that all three acetate hydrogens were incorporated into the acetyl-derived starter units for both the nonaketide and diketide moieties in lovastatin (15). The purified LovB can use malonyl-CoA for both chain priming and chain elongation, loading malonate with decarboxylation to make the acetyl starter unit. Although LovB is able to prime with and elongate the chain by two further condensations with malonyl-CoA, in the absence of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), no ketoreduction occurs. The dominant product is lactone 3 (Fig. 2A, trace i), which forms by enolization and cyclization with off-loading of the unreduced triketide. Addition of NADPH to this system enables function of the KR domain. In this and subsequent experiments, the malonyl-CoA could be conveniently synthesized in situ by malonyl-CoA synthase (MatB) from *Rhizobium trifoli* using free malonate and CoA (16). With KR enabled, LovB makes penta-, hexa-, and heptaketide pyrones 4 to 6, as well as ketones 7 and 8 (Fig. 2A, trace ii). The structures were confirmed by chemical synthesis of authentic standards, except for heptaketide 6, which proved very unstable. However, the mass increase of 26 atomic mass units for 6 and its red shift in the ultraviolet spectrum when compared to 5 are consistent with its proposed heptaketide pyrone structure (table S3). Compounds 7 and 8 result from progressive decarboxylation and dehydration of the ACP at the β-keto stage. The resulting β-keto acids spontaneously decarboxylate to afford 7 and 8. Formation of compounds 4 to 8 illustrates that derailment in the normal programmed steps, namely the lack of methylation due to the absence of S-adenosylmethionine.

References

1Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA.
2Department of Chemistry, University of Alberta, Edmonton, Alberta, T6G 2G2, Canada.
3Department of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA.
4Amnis Biotechnologies, 5805 Hollis Street, Suite 100, Emeryville, CA 94608, USA.
*To whom correspondence should be addressed. E-mail: john.vederas@ualberta.ca (J.C.V.); yitang@ucula.edu (Y.T.)

www.sciencemag.org SCIENCE VOL 326 23 OCTOBER 2009